Vijenthira A, Kuruvilla J, Crump M, Jain M, et al. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk J Clin Oncol 2022 Oct 31:JCO2200478. doi: 10.1200/JCO.22.00478.
PMID: 36315922